Ipamorelin: The Cleanest Ghrelin Agonist for GH Release

Why Ipamorelin Earned the “Cleanest GHRP” Reputation

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed by Novo Nordisk in the late 1990s. It was specifically engineered for one property: receptor selectivity. The earlier GHRPs (GHRP-2, GHRP-6, hexarelin) all activate GHSR-1a and trigger GH release — but they also cross-activate adrenocorticotropic hormone (ACTH) and prolactin pathways, raising cortisol and prolactin alongside GH. That cortisol crosstalk is why GHRP-2 users report water retention, irritability, and abdominal fat resistance over long cycles.

Ipamorelin was the first ghrelin agonist where head-to-head clinical comparisons showed GH release equivalent to GHRP-2, with no statistically significant elevation in cortisol, prolactin, or ACTH at doses up to 200 mcg. That’s the entire pitch — and twenty years later it has held up.

The Biochemistry That Makes Selectivity Possible

GHSR-1a is a Gq-protein-coupled receptor expressed densely on pituitary somatotrophs and, in lower density, on hypothalamic neurons regulating appetite (arcuate nucleus) and the adrenal axis. Activation triggers phospholipase C, generating IP3 and diacylglycerol, mobilizing intracellular calcium, and driving GH vesicle exocytosis.

Ipamorelin’s selectivity comes from its binding kinetics — it activates the pituitary somatotroph GHSR-1a but binds with much lower affinity to the hypothalamic and corticotroph populations. Studies measuring ACTH and cortisol AUC after ipamorelin dosing show no significant elevation above placebo at 0.3–2 mcg/kg, while GH AUC rises 4–8 fold. Peak GH typically hits 8–15 ng/mL within 20–30 minutes of subcutaneous injection. Serum half-life is approximately 2 hours, with biologic action concentrated in the first 90 minutes.

The somatostatin angle is what makes the CJC-1295 stack so synergistic: ipamorelin not only triggers GH release directly, it also suppresses hypothalamic somatostatin (the brake pedal on GH). Removing the brake while pressing the accelerator (CJC-1295 driving the GHRH receptor) is the textbook expression of a key biochemistry law.

Tony Huge Laws of Biochemistry Physics — Law 1 Applied

Per the Tony Huge Laws of Biochemistry Physics, Law 1 — Governors vs Accelerators describes ipamorelin’s mechanism precisely. Growth hormone output is controlled by two opposing systems: GHRH (accelerator) and somatostatin (governor / brake). Most people who try to “boost GH” only push the accelerator — they take CJC-1295 or sermorelin and wonder why response plateaus. The plateau happens because somatostatin scales up in response to GHRH stimulation, applying the brake harder.

Ipamorelin attacks the brake. It suppresses somatostatin while simultaneously triggering GH release through the parallel ghrelin pathway. Pairing CJC-1295 (accelerator) with ipamorelin (brake removal) is how you produce a GH pulse 3–5x larger than either alone. The car only moves fast when you release the parking brake. Law 1 in clinical form.

Natural Plus Protocol

Dosing: 100–300 mcg subcutaneous, 1–3 times daily. The classic stack is 100 mcg ipamorelin + 100 mcg CJC-1295 (Modified GRF 1-29) per shot. For body composition cycles, 200 mcg per shot is common. Going above 300 mcg per dose produces no additional GH release — receptor saturation.

Cycle: 8–12 weeks on, 4 weeks off. Ipamorelin is gentle enough that some users run it continuously, but cycling preserves long-term receptor sensitivity.

Timing: Pre-bed dose is the highest-value injection — stacks with natural slow-wave-sleep GH pulse. Morning fasted is the second priority. A pre-workout dose adds lipolysis during training. Always wait 20–30 minutes after injection before eating; insulin and fatty acids both blunt GH release.

Bloodwork: Baseline IGF-1, repeat at week 4 and week 12. Target 250–350 ng/mL for men 30–45, 200–300 ng/mL for men 45+. Track fasting glucose and HbA1c quarterly.

Cycle support: No HPG suppression — no PCT needed. No need for Defend or BLACK OX. Standard hydration and electrolyte support is sufficient.

Stacking Recommendations

Target Audience

Ipamorelin is the right choice for men starting their first peptide cycle, athletes sensitive to cortisol load, and anyone who tried GHRP-2 and disliked the hunger and water retention. It’s also the GHRP of choice for women on biohacking protocols — minimal cortisol means minimal disruption to female endocrine cycles. Older men (50+) on TRT who want recovery and sleep benefits without aggressive IGF-1 push are an ideal demographic.

Not appropriate for: active malignancy, severe insulin resistance without dietary discipline, or anyone who refuses subcutaneous injection (MK-677 is the oral alternative, with different tradeoffs).

Timeline: What to Expect

Interesting Perspectives

The selectivity that aged well: Ipamorelin was developed for a pediatric GH-deficiency indication that Novo Nordisk eventually abandoned for commercial reasons. The molecule sat dormant in the patent literature for years before peptide compounders rediscovered it. Twenty years of off-label use have validated the original selectivity claim — adverse-event databases show no signal for cortisol-related effects or hyperprolactinemia at therapeutic doses.

The cortisol math nobody runs: A typical GHRP-2 user adds an estimated 15-20% to daily cortisol AUC. Over a 12-week cycle, that’s the equivalent of mild chronic stress — and the abdominal fat resistance most GHRP-2 users complain about is exactly what chronic cortisol does. Switching to ipamorelin removes that variable entirely. Many “non-responders” to GHRP cycles are actually cortisol-driven recomposition failures.

Cross-domain insight — sleep architecture: EEG studies of ipamorelin users show increased N3 (slow-wave sleep) duration, the stage where natural GH pulses peak. This isn’t placebo. It’s the peptide stacking with your own pulsatile rhythm. The recovery benefits Enhanced Men attribute to “the peptides” are largely the downstream of better N3 sleep.

Contrarian take: If you can only run ONE compound from the GH-axis stack, ipamorelin is the wrong choice — CJC-1295 produces a bigger acute pulse. But almost nobody runs just one. The right question is “which GHRP do I stack with my GHRH” — and the answer is ipamorelin every time.

FAQ

What is ipamorelin? Ipamorelin is a synthetic pentapeptide that activates the ghrelin receptor on pituitary somatotrophs, triggering selective growth hormone release without elevating cortisol, prolactin, or appetite.

What is the standard ipamorelin dose? 100-300 mcg subcutaneous, 1-3 times daily, typically stacked with 100 mcg CJC-1295. Doses above 300 mcg per shot produce no additional GH release due to receptor saturation.

Does ipamorelin raise cortisol? Clinical studies show no statistically significant cortisol or prolactin elevation at therapeutic doses (0.3-2 mcg/kg), making it the most receptor-selective GHRP available.

Should I stack ipamorelin with CJC-1295? Yes — they activate independent receptor pathways (GHSR-1a and GHRH receptor) and remove different brakes on GH release, producing 3-5x larger GH pulses than either alone.

Who should use ipamorelin? Enhanced Men over 30 seeking GH-axis amplification without cortisol or prolactin crosstalk. Especially suitable for first-time peptide users, athletes on TRT, and biohackers prioritizing sleep depth and recovery.

Related Reading on tonyhuge.is

Start with the Enhanced Athlete Protocol — Peptides hub for the full GH-axis framework. The CJC-1295 vs ipamorelin comparison covers stacking logic in depth. Read Tony Huge Law 1 — Governors vs Accelerators for the foundational framework this article applies. For bloodwork standards, see the Enhanced Athlete Protocol — Bloodwork hub.